Board of Directors

  • Larry Ellberger
    Chairman

  • Keith L. Brownlie
    Former Partner, Ernst & Young LLP

  • Herbert J. Conrad
    Former President, Roche Pharmaceuticals US

  • James J. Marino, J.D.
    Former Partner, Dechert LLP

  • Anthony S. Marucci
    Founder, President, Chief Executive Officer and Director

  • Gerald McMahon, Ph.D.
    Former President and CEO, Kolltan Pharmaceuticals

  • Harry H. Penner, Jr., J.D., L.L.M.
    Chairman and CEO, Nascent Bioscience

  • Karen L. Shoos, J.D.
    Consultant, AABB International Technical Assistance, Division of Global Services

  • Larry Ellberger
    Chairman

  • Keith L. Brownlie
    Former Partner, Ernst & Young LLP

  • Herbert J. Conrad
    Former President, Roche Pharmaceuticals US

  • James J. Marino, J.D.
    Former Partner, Dechert LLP

  • Anthony S. Marucci
    Founder, President, Chief Executive Officer and Director

  • Gerald McMahon, Ph.D.
    Former President and CEO, Kolltan Pharmaceuticals

  • Harry H. Penner, Jr., J.D., L.L.M.
    Chairman and CEO, Nascent Bioscience

  • Karen L. Shoos, J.D.
    Consultant, AABB International Technical Assistance, Division of Global Services

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline